Influence of AFP on Surgical Outcomes in Non-B Non-C Patients with Curative Resection for Hepatocellular Carcinoma

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2022 Mar 16

PMID 35293607

Authors

Xiao-Ping Tan

Kai Zhou

Qing-Li Zeng

Yun-Fei Yuan

Wei Chen

Affiliations

Soon will be listed here.

Abstract

To study the clinical and prognostic features of non-B non-C alpha-fetoprotein (AFP)(-)-hepatocellular carcinoma (HCC) (NBNC-AFP(-)-HCC) and the relationship between the prognostic features of HCC and hepatitis B virus surface antigen (HBsAg) status and AFP. We enrolled 227 patients who underwent hepatic resection for HCC between January 1998 and December 2007 at Sun Yat-sen University Cancer Center, all of whom were diagnosed with HCC by pathology. All patients were stratified into one of four groups (B-AFP(+)-HCC, B-AFP(-)-HCC, NBNC-AFP(+)-HCC, and NBNC-AFP(-)-HCC) according to AFP levels and HBsAg status. The clinicopathologic and survival characteristics of NBNC-AFP(-)-HCC patients were compared with those of all other three groups. Out of the 105 NBNC-HCC patients, 43 patients (40.9%) had AFP-negative HCC. There were some differences in factors between the B-AFP(+) and NBNC-AFP(-) patients, such as age, body mass index (BMI), diabetes, and ALT (P < 0.05). On univariate analysis, tumour size, secondary tumour, and portal invasion were prognostic factors for overall survival (OS) and disease-free survival (DFS) (P < 0.05). Cox multivariate regression analysis suggested that tumour size and tumour number (P < 0.05) were independent predictors. In addition, compared with the B-AFP(+)-HCC, B-AFP(-)-HCC, and NBNC-AFP(+)-HCC groups, the NBNC-AFP(-)-HCC patients had the best DFS (P < 0.05). Compared with the B-AFP(+)-HCC and NBNC-AFP(+)-HCC groups, the NBNC-AFP(-)-HCC patients had better OS (P < 0.05), and survival rates were similar to those of B-AFP(-)-HCC patients. NBNC-AFP(-)-HCC patients had a relatively favourable prognosis. It can serve as a useful marker in predicting the risk of tumour recurrence in the early stages.

References

Nie W, Yan L, Lee Y, Guha C, Kurland I, Lu H . Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma. Mass Spectrom Rev. 2014; 35(3):331-49. DOI: 10.1002/mas.21439. View

Jou J, Diehl A . Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Clin Invest. 2010; 120(4):1031-4. PMC: 2846072. DOI: 10.1172/JCI42615. View

Hennedige T, Venkatesh S . Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013; 12:530-47. PMC: 3666429. DOI: 10.1102/1470-7330.2012.0044. View

Zhang W, Tan Y, Jiang L, Yan L, Yang J, Li B . Prognostic nomogram for patients with non-B non-C hepatocellular carcinoma after curative liver resection. Int J Surg. 2017; 44:160-165. DOI: 10.1016/j.ijsu.2017.06.041. View

Younossi Z, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M . Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015; 62(6):1723-30. DOI: 10.1002/hep.28123. View

El-Serag H, Tran T, Everhart J . Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126(2):460-8. DOI: 10.1053/j.gastro.2003.10.065. View

Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T . Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2011; 107(2):253-61. DOI: 10.1038/ajg.2011.327. View

Patton H, Yates K, Unalp-Arida A, Behling C, Huang T, Rosenthal P . Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2010; 105(9):2093-102. PMC: 3070291. DOI: 10.1038/ajg.2010.152. View

Ochiai T, Ogino S, Ishimoto T, Toma A, Yamamoto Y, Morimura R . Prognostic impact of hepatectomy for patients with non-hepatitis B, non-hepatitis C hepatocellular carcinoma. Anticancer Res. 2014; 34(8):4399-410. View

10.

Iida H, Aihara T, Ikuta S, Yamanaka N . Clinicopathological characteristics of hepatitis B surface antigen-negative and hepatitis C antibody-negative hepatocellular carcinoma. Oncol Lett. 2015; 10(4):2233-2238. PMC: 4579965. DOI: 10.3892/ol.2015.3562. View

11.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

12.

Niederau C . Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol. 2014; 20(33):11595-617. PMC: 4155353. DOI: 10.3748/wjg.v20.i33.11595. View

13.

Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N . Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Ann Surg. 2013; 259(2):336-45. DOI: 10.1097/SLA.0b013e31829291e9. View

14.

Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M . Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997; 336(26):1855-9. DOI: 10.1056/NEJM199706263362602. View

15.

Nishikawa H, Osaki Y . Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol. 2013; 43(5):1333-42. DOI: 10.3892/ijo.2013.2061. View

16.

Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N . A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 2014; 261(3):513-20. DOI: 10.1097/SLA.0000000000000821. View

17.

Wu Z, Xu Z, Li W, Zhang H, Yang N, Yao X . Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. J Surg Res. 2014; 193(1):153-60. DOI: 10.1016/j.jss.2014.07.021. View

18.

Fan J, Farrell G . Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2008; 50(1):204-10. DOI: 10.1016/j.jhep.2008.10.010. View

19.

Shinkawa H, Uenishi T, Takemura S, Ohba K, Ogawa M, Ichikawa T . Risk factors for postoperative recurrence of non-B non-C hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2009; 17(3):291-5. DOI: 10.1007/s00534-009-0186-3. View

20.

Farrell G, Chitturi S, Lau G, Sollano J . Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007; 22(6):775-7. DOI: 10.1111/j.1440-1746.2007.05002.x. View